Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Clifford

Showing results (231-240 of 325) with videos related to

Pageof 33
Sort By:
Viruses|December 23, 2023
Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIVPatricia K Riggs, Albert M Anderson, Bin Tang, et al.
JAMA Neurology|September 1, 2018
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus GroupBarney J Stern, Walter Royal, Jeffrey M Gelfand, et al.
Archives of Neurology|May 12, 2010
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER StudyRonald J Ellis, Debralee Rosario, David B Clifford, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2022
Higher Levels of Cerebrospinal Fluid and Plasma Neurofilament Light in Human Immunodeficiency Virus-Associated Distal Sensory PolyneuropathyRonald J Ellis, Ahmed Chenna, Yolanda Lie, et al.
Plos Clinical Trials|April 3, 2007
Factors in AIDS dementia complex trial design: results and lessons from the abacavir trialBruce J Brew, Mark Halman, Jose Catalan, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Neurology|May 5, 2021
Large Mitochondrial DNA Deletions in HIV Sensory NeuropathyRicardo H Roda, David Bargiela, Weiran Chen, et al.
Journal of Neurovirology|February 14, 2022
Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluidDipesh Solanky, Jerel A Fields, Jennifer E Iudicello, et al.
Pageof 33

Showing results (231-240 of 325) with videos related to

Sort By:
Pageof 33
Viruses|December 23, 2023
Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIVPatricia K Riggs, Albert M Anderson, Bin Tang, et al.
JAMA Neurology|September 1, 2018
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus GroupBarney J Stern, Walter Royal, Jeffrey M Gelfand, et al.
Archives of Neurology|May 12, 2010
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER StudyRonald J Ellis, Debralee Rosario, David B Clifford, et al.
Journal of Neurovirology|January 6, 2016
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort studyEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2022
Higher Levels of Cerebrospinal Fluid and Plasma Neurofilament Light in Human Immunodeficiency Virus-Associated Distal Sensory PolyneuropathyRonald J Ellis, Ahmed Chenna, Yolanda Lie, et al.
Plos Clinical Trials|April 3, 2007
Factors in AIDS dementia complex trial design: results and lessons from the abacavir trialBruce J Brew, Mark Halman, Jose Catalan, et al.
American Journal of Epidemiology|June 27, 2014
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIVEdward R Hammond, Rosa M Crum, Glenn J Treisman, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Neurology|May 5, 2021
Large Mitochondrial DNA Deletions in HIV Sensory NeuropathyRicardo H Roda, David Bargiela, Weiran Chen, et al.
Journal of Neurovirology|February 14, 2022
Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluidDipesh Solanky, Jerel A Fields, Jennifer E Iudicello, et al.
Pageof 33